Stockreport

Why Analysts Think Nektar Therapeutics Could Be Undervalued After Rezpeg Trial Momentum Grows [Yahoo! Finance]

Nektar Therapeutics  (NKTR) 
Last nektar therapeutics earnings: 2/27 04:15 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.nektar.com/investor-relations
PDF The shift reflects growing confidence in Rezpeg's commercial potential and added indications, partially offset by caution around how quickly those opportunities may tran [Read more]